Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
June 19, 2010
On the complexity of discrete feature selection for optimal classification
Jose M Peña, Roland Nilsson
Expert Opinion on Investigational Drugs
|
May 20, 2017
New antivirals for the treatment of chronic hepatitis B
Vincent Soriano, Pablo Barreiro, Laura Benitez, et al.
Plos One
|
June 25, 2015
The influence of synaptic size on AMPA receptor activation: a Monte Carlo model
Jesus Montes, Jose M Peña, Javier DeFelipe, et al.
Brain Informatics
|
October 18, 2016
Predicting the post-treatment recovery of patients suffering from traumatic brain injury (TBI)
Zaigham Faraz Siddiqui, Georg Krempl, Myra Spiliopoulou, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
July 29, 2017
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C
Vicente Soriano, Laura Benítez-Gutiérrez, Ana Arias, et al.
Antiviral Therapy
|
March 30, 2017
Decline and changing profile of hepatitis delta among injection drug users in Spain
Antonio Aguilera, Rocio Trastoy, Pablo Barreiro, et al.
Acta Obstetricia Et Gynecologica Scandinavica
|
May 9, 2007
Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003
Covadonga Martí, Jose M Peña, Isabel Bates, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2006
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
Jose M Miro, Juan C Lopez, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2004
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
Federico Pulido, Jose R Arribas, Jose M Miró, et al.
AIDS (London, England)
|
July 20, 2002
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)
Jose R Arribas, Federico Pulido, Jose M Miró, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
IEEE Transactions on Pattern Analysis and Machine Intelligence
|
June 19, 2010
On the complexity of discrete feature selection for optimal classification
Jose M Peña, Roland Nilsson
Expert Opinion on Investigational Drugs
|
May 20, 2017
New antivirals for the treatment of chronic hepatitis B
Vincent Soriano, Pablo Barreiro, Laura Benitez, et al.
Plos One
|
June 25, 2015
The influence of synaptic size on AMPA receptor activation: a Monte Carlo model
Jesus Montes, Jose M Peña, Javier DeFelipe, et al.
Brain Informatics
|
October 18, 2016
Predicting the post-treatment recovery of patients suffering from traumatic brain injury (TBI)
Zaigham Faraz Siddiqui, Georg Krempl, Myra Spiliopoulou, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
July 29, 2017
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C
Vicente Soriano, Laura Benítez-Gutiérrez, Ana Arias, et al.
Antiviral Therapy
|
March 30, 2017
Decline and changing profile of hepatitis delta among injection drug users in Spain
Antonio Aguilera, Rocio Trastoy, Pablo Barreiro, et al.
Acta Obstetricia Et Gynecologica Scandinavica
|
May 9, 2007
Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003
Covadonga Martí, Jose M Peña, Isabel Bates, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2006
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
Jose M Miro, Juan C Lopez, Daniel Podzamczer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2004
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
Federico Pulido, Jose R Arribas, Jose M Miró, et al.
AIDS (London, England)
|
July 20, 2002
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)
Jose R Arribas, Federico Pulido, Jose M Miró, et al.
Page
of 1